The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Elevated pretreatment serum CA9 (carbonic anhydrase 9) and correlation with progression-free and overall survival in trastuzumab-treated metastatic breast cancer.
K. Leitzel
No relevant relationships to disclose
H. Y. Hou
No relevant relationships to disclose
U. Anyanwu
No relevant relationships to disclose
V. Shrivastava
No relevant relationships to disclose
M. S. Evans
No relevant relationships to disclose
S. M. Ali
No relevant relationships to disclose
W. Koestler
No relevant relationships to disclose
E. Fuchs
No relevant relationships to disclose
F. J. Esteva
No relevant relationships to disclose
W. P. Carney
No relevant relationships to disclose
A. Lipton
No relevant relationships to disclose